ClinicalTrials.gg
CompletedNCT01438957Updated Mar 22, 2021Results posted

Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery With Epidural Anesthesia or Spinal Anesthesia Without Intubation

A Phase 3 interventional study of Dexmedetomidine hydrochloride and Placebo in Sedation, sponsored by Pfizer. Completed at 12 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-03-22.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2011, registered Sep 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

The purpose of this study is to examine the efficacy and safety of DA-9501 (Dexmedetomidine) in patients who require sedation during the surgery that requires epidural or spinal anesthesia without intubation under monitored sedation care.

Read the detailed description

Phase III, randomized, placebo controlled, double blind, parallel comparative study (Therapeutic confirmatory trial), to evaluate the efficacy and the safety of Dexmedetomidine in non-intubated patients who require sedation during surgery with spinal or epidural anesthesia under monitored sedation care

02

Conditions studied

  • Sedation

Keywords

  • Dexmedetomidine
  • Sedation
  • Non-intubation
  • epidural anesthesia
  • spinal anesthesia
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient has signed and dated the after the study had been fully explained.
  2. Patient is male or female, at least 20 years of age when the Informed Consent is obtained.
  3. American Society for Anesthesiologists (ASA) I to III Class.
  4. Patient who requires sedation during the elective surgery which requires ≥30mins (expected time) without intubation under monitored sedation care.
  5. Patient undergoing a surgery requiring epidural or spinal anesthesia

Exclusion criteria

Exclusion Criteria:

  1. Patient who underwent general anesthesia within 7 days, or who received other study drugs within 30 days from the date of consent.
  2. Patient with \<92% SpO2, at the physical examination prior to the study drug administration, or ventilatory failure which requires intubation or Laryngeal Mask.
  3. Patient with central nervous system pathology which may lead to increased intracranial pressure, uncontrolled seizures, psychiatric disorder which may be confused with the response to sedation treatment.
  4. Patient who require general anesthesia.
  5. Patient who receives treatment by alpha-2 agonists or alpha-2 antagonists within seven days of scheduled surgery or procedure.
  6. Patient in whom opioids, DA-9501 or other alpha-2 agonists, or drugs which may be used in the study are .
  7. Patient diagnosed with unstable angina or acute myocardiac infarction within 6 weeks from the date of consent.
  8. Patient whose heart rate is \<60 bpm, systolic blood pressure is \<90 mmHg by the physical examination prior to the study drug administration.
  9. Patient has third degree heart block, unless the patient has a pacemaker or transverse pacing wires are in place.
  10. Patient who has experienced an increase in (ALT) and / or aspartate aminotransferase (AST) more than double the upper normal limit within 2 months of the date of consent, or who has a history of liver insufficiency.
  11. Pregnant or lactating woman.
  12. In the Investigator's or subinvestigator's opinion, the patient has any symptom or condition which might increase risk to the patient by conducting the study or preclude obtaining satisfactory study data
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
119 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Dexmedetomidine 0 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0 mcg/kg/hr Maintenance dose

    Drug: Placebo

  • Experimental
    Dexmedetomidine 0.067 mcg/kg

    Dexmedetomidine 0.4 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose

    Drug: Dexmedetomidine hydrochloride

  • Experimental
    Dexmedetomidine 0.25 mcg/kg

    Dexmedetomidine 1.5 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose

    Drug: Dexmedetomidine hydrochloride

  • Experimental
    Dexmedetomidine 0.5 mcg/kg

    Dexmedetomidine 3 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose

    Drug: Dexmedetomidine hydrochloride

  • Experimental
    Dexmedetomidine 1.0 mcg/kg

    Dexmedetomidine 6 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose

    Drug: Dexmedetomidine hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Who Did Not Require Rescue Administration of Propofol to Achieve and Maintain Observer's Assessment of Alertness/Sedation (OAA/S) Score ≤4 During the Study Drug Administration.

    Time frame: Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.

Secondary outcomes

  1. Number of Propofol Dosing Required to Achieve and Maintain OAA/S Score ≤4 During the Study Drug Administration

    Time frame: 15 minutes after the start of study drug, if the OAA/S score is 5.

  2. Dosage of Propofol Dosing Required to Achieve and Maintain OAA/S Score ≤4 During the Study Drug Administration

    Time frame: 15 minutes after the start of study drug, if the OAA/S score is 5.

  3. Time to First Rescue Administration of Propofol

    Time frame: During the study drug infusion period (≥15 minutes [Approximate])

  4. Percentage of Patients Who Did Not Require Rescue Administration of Fentanyl During the Study Drug Administration

    Time frame: After the surgery start, the administration of fentanyl is permissible as required to treat pain. In case of repeated dose, the dosing interval should be ≥15 minutes.

  5. Number of Fentanyl Dosing Required During the Study Drug Administration.

    Time frame: During the study drug administration

  6. Dosage of Fentanyl Dosing Required During the Study Drug Administration.

    Time frame: During the study drug administration

  7. Percentage of Time Spent OAA/S Score ≤4 During the Study Drug Infusion

    Time frame: Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.

  8. Percentage of Time Spent OAA/S Score 3 to 4 During the Study Drug Infusion

    Time frame: Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.

  9. Time to Attain the Point Where Patient is Recovered Assessed by Aldrete Score Following Discontinuation of the Study Drug Infusion

    Time frame: Every 15 ± 2 minutes until the score of each item becomes ≥1 and the total value becomes ≥8.

  10. Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Easiness of Maintenance of Sedation Level)

    VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.

    Time frame: Within 24 hours after completion of the study drug administration

  11. Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Stability of Hemodynamic State)

    VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.

    Time frame: Within 24 hours after completion of the study drug administration

  12. Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Stability of Respiratory State)

    VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.

    Time frame: Within 24 hours after completion of the study drug administration

  13. Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Subject's Cooperation)

    VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.

    Time frame: Within 24 hours after completion of the study drug administration

  14. Score Evaluation of Satisfaction and Anxiety of the Subject ("I Was Satisfied With This Anesthesia Procedure")

    Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.

    Time frame: Within 24 hours after completion of the study drug administration (as much as possible)

  15. Score Evaluation of Satisfaction and Anxiety of the Subject ("I Did Not Feel Pain During the Surgery")

    Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.

    Time frame: Within 24 hours after completion of the study drug administration (as much as possible)

  16. Score Evaluation of Satisfaction and Anxiety of the Subject ("If You May Undergo a Similar Surgery, the Same Anesthesia Procedure Will be Requested for the Next Time")

    Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.

    Time frame: Within 24 hours after completion of the study drug administration (as much as possible)

  17. Score Evaluation of Satisfaction and Anxiety of the Subject ("Assess the Anxiety Level Before Surgery")

    Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.

    Time frame: Within 24 hours after completion of the study drug administration (as much as possible)

  18. Score Evaluation of Satisfaction and Anxiety of the Subject ("Assess the Anxiety Level During Surgery")

    Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.

    Time frame: Within 24 hours after completion of the study drug administration (as much as possible)

  19. Score Evaluation of Satisfaction and Anxiety of the Subject ("Assess the Anxiety Level After Surgery")

    Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.

    Time frame: Within 24 hours after completion of the study drug administration (as much as possible)

07

Results

Posted Mar 22, 2021

Participant flow

Participant flow — Overall Study
MilestonePlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Started2223242525
Completed2122242425
Not completed11010
Withdrew: Physician decision11010

Outcome measures

PrimaryPercentage of Patients Who Did Not Require Rescue Administration of Propofol to Achieve and Maintain Observer's Assessment of Alertness/Sedation (OAA/S) Score ≤4 During the Study Drug Administration.
Time frame:
Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.
Reported as:
Number · Percentage of participants
Percentage of Patients Who Did Not Require Rescue Administration of Propofol to Achieve and Maintain Observer's Assessment of Alertness/Sedation (OAA/S) Score ≤4 During the Study Drug Administration.
Percentage of participantsPlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Percentage of Patients Who Did Not Require Rescue Administration of Propofol to Achieve and Maintain Observer's Assessment of Alertness/Sedation (OAA/S) Score ≤4 During the Study Drug Administration.22.7 (7.8 to 45.4)13.0 (2.8 to 33.6)45.8 (25.6 to 67.2)68.0 (46.5 to 85.1)80.0 (59.3 to 93.2)
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Mantel Haenszel · p = <0.001Stratified by the anesthesia type
  • Placebo vs Dexmedetomidine 0.5 mcg/kg · Mantel Haenszel · p = 0.003Stratified by the anesthesia type
  • Placebo vs Dexmedetomidine 0.25 mcg/kg · Mantel Haenszel · p = 0.086Stratified by the anesthesia type
  • Placebo vs Dexmedetomidine 0.067 mcg/kg vs Dexmedetomidine 0.25 mcg/kg vs Dexmedetomidine 0.5 mcg/kg vs Dexmedetomidine 1.0 mcg/kg · Mantel-extension test · p = <0.001Stratified by the anesthesia type
SecondaryNumber of Propofol Dosing Required to Achieve and Maintain OAA/S Score ≤4 During the Study Drug Administration
Time frame:
15 minutes after the start of study drug, if the OAA/S score is 5.
Reported as:
Mean · Number of dosing
Number of Propofol Dosing Required to Achieve and Maintain OAA/S Score ≤4 During the Study Drug Administration
Number of dosingPlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Number of Propofol Dosing Required to Achieve and Maintain OAA/S Score ≤4 During the Study Drug Administration5.1 ± 4.73.7 ± 3.41.9 ± 2.30.8 ± 1.50.5 ± 1.2
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Mantel Haenszel · p = <0.001Stratified by the anesthesia type
  • Placebo vs Dexmedetomidine 0.5 mcg/kg · Mantel Haenszel · p = <0.001Stratified by the anesthesia type
  • Placebo vs Dexmedetomidine 0.25 mcg/kg · Mantel Haenszel · p = 0.006Stratified by the anesthesia type
  • Placebo vs Dexmedetomidine 0.067 mcg/kg · Mantel Haenszel · p = 0.329Stratified by the anesthesia type
SecondaryDosage of Propofol Dosing Required to Achieve and Maintain OAA/S Score ≤4 During the Study Drug Administration
Time frame:
15 minutes after the start of study drug, if the OAA/S score is 5.
Reported as:
Mean · mg/kg
Dosage of Propofol Dosing Required to Achieve and Maintain OAA/S Score ≤4 During the Study Drug Administration
mg/kgPlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Dosage of Propofol Dosing Required to Achieve and Maintain OAA/S Score ≤4 During the Study Drug Administration1.019 ± 0.9330.744 ± 0.6750.373 ± 0.4590.166 ± 0.2980.096 ± 0.231
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Mantel Haenszel · p = <0.001Stratified by the anesthesia type
  • Placebo vs Dexmedetomidine 0.5 mcg/kg · Mantel Haenszel · p = <0.001Stratified by the anesthesia type
  • Placebo vs Dexmedetomidine 0.25 mcg/kg · Mantel Haenszel · p = 0.006Stratified by the anesthesia type
  • Placebo vs Dexmedetomidine 0.067 mcg/kg · Mantel Haenszel · p = 0.371Stratified by the anesthesia type
SecondaryTime to First Rescue Administration of Propofol
Time frame:
During the study drug infusion period (≥15 minutes [Approximate])
Reported as:
Median · minutes
Time to First Rescue Administration of Propofol
minutesPlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Time to First Rescue Administration of Propofol25.5 (20.0 to 46.0)20 (20.0 to 22.0)24 (21.0 to NA)NA (61.0 to NA)NA (NA to NA)
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Log Rank · p = <0.001Stratified by the anesthesia type
  • Placebo vs Dexmedetomidine 0.5 mcg/kg · Log Rank · p = 0.001Stratified by the anesthesia type
  • Placebo vs Dexmedetomidine 0.25 mcg/kg · Log Rank · p = 0.212Stratified by the anesthesia type
SecondaryPercentage of Patients Who Did Not Require Rescue Administration of Fentanyl During the Study Drug Administration
Time frame:
After the surgery start, the administration of fentanyl is permissible as required to treat pain. In case of repeated dose, the dosing interval should be ≥15 minutes.
Reported as:
Number · Percentage of participants
Percentage of Patients Who Did Not Require Rescue Administration of Fentanyl During the Study Drug Administration
Percentage of participantsPlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Percentage of Patients Who Did Not Require Rescue Administration of Fentanyl During the Study Drug Administration95.5 (77.2 to 99.9)91.3 (72.0 to 98.9)100.0 (85.8 to 100.0)96.0 (79.6 to 99.9)96.0 (79.6 to 99.9)
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Mantel Haenszel · p = 0.869Stratified by the anesthesia type
SecondaryNumber of Fentanyl Dosing Required During the Study Drug Administration.
Time frame:
During the study drug administration
Reported as:
Mean · Number of dosing
Number of Fentanyl Dosing Required During the Study Drug Administration.
Number of dosingPlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Number of Fentanyl Dosing Required During the Study Drug Administration.0.1 ± 0.60.2 ± 0.70.0 ± 0.00.0 ± 0.20.1 ± 0.6
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Mantel Haenszel · p = 0.897Stratified by the anesthesia type
SecondaryDosage of Fentanyl Dosing Required During the Study Drug Administration.
Time frame:
During the study drug administration
Reported as:
Mean · mcg/kg
Dosage of Fentanyl Dosing Required During the Study Drug Administration.
mcg/kgPlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Dosage of Fentanyl Dosing Required During the Study Drug Administration.0.068 ± 0.3200.085 ± 0.3170.000 ± 0.0000.018 ± 0.0880.061 ± 0.304
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Mantel Haenszel · p = 0.897Stratified by the anesthesia type
SecondaryPercentage of Time Spent OAA/S Score ≤4 During the Study Drug Infusion
Time frame:
Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.
Reported as:
Mean · Percentage of time
Percentage of Time Spent OAA/S Score ≤4 During the Study Drug Infusion
Percentage of timePlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Percentage of Time Spent OAA/S Score ≤4 During the Study Drug Infusion50.17 ± 23.8858.15 ± 20.7161.44 ± 18.2870.07 ± 21.0876.78 ± 14.07
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Mantel Haenszel · p = <0.001Stratified by the anesthesia type
  • Placebo vs Dexmedetomidine 0.5 mcg/kg · Mantel Haenszel · p = 0.002Stratified by the anesthesia type
  • Placebo vs Dexmedetomidine 0.25 mcg/kg · Mantel Haenszel · p = 0.116Stratified by the anesthesia type
SecondaryPercentage of Time Spent OAA/S Score 3 to 4 During the Study Drug Infusion
Time frame:
Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.
Reported as:
Mean · Percentage of time
Percentage of Time Spent OAA/S Score 3 to 4 During the Study Drug Infusion
Percentage of timePlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Percentage of Time Spent OAA/S Score 3 to 4 During the Study Drug Infusion47.88 ± 25.3156 ± 19.8753.66 ± 17.565.3 ± 20.6362.25 ± 23.14
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Mantel Haenszel · p = 0.088Stratified by the anesthesia type
SecondaryTime to Attain the Point Where Patient is Recovered Assessed by Aldrete Score Following Discontinuation of the Study Drug Infusion
Time frame:
Every 15 ± 2 minutes until the score of each item becomes ≥1 and the total value becomes ≥8.
Reported as:
Median · Minutes
Time to Attain the Point Where Patient is Recovered Assessed by Aldrete Score Following Discontinuation of the Study Drug Infusion
MinutesPlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Time to Attain the Point Where Patient is Recovered Assessed by Aldrete Score Following Discontinuation of the Study Drug Infusion15 (NA to NA)15 (NA to NA)15 (15.0 to 16.0)15 (NA to NA)15 (NA to NA)
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Log Rank · p = 0.085Stratified by the anesthesia type
SecondaryVisual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Easiness of Maintenance of Sedation Level)

VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.

Time frame:
Within 24 hours after completion of the study drug administration
Reported as:
Mean · Scores on a scale
Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Easiness of Maintenance of Sedation Level)
Scores on a scalePlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Easiness of Maintenance of Sedation Level)5.85 ± 3.544.36 ± 3.413.73 ± 3.192.81 ± 2.642.65 ± 2.98
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Mantel Haenszel · p = 0.005Stratified by the anesthesia type
  • Placebo vs Dexmedetomidine 0.5 mcg/kg · Mantel Haenszel · p = 0.014Stratified by the anesthesia type
  • Placebo vs Dexmedetomidine 0.25 mcg/kg · Mantel Haenszel · p = 0.055Stratified by the anesthesia type
SecondaryVisual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Stability of Hemodynamic State)

VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.

Time frame:
Within 24 hours after completion of the study drug administration
Reported as:
Mean · Scores on a scale
Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Stability of Hemodynamic State)
Scores on a scalePlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Stability of Hemodynamic State)2.05 ± 2.213.3 ± 3.191.68 ± 1.461.72 ± 2.141.47 ± 1.41
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Mantel Haenszel · p = 0.737Stratified by the anesthesia type
SecondaryVisual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Stability of Respiratory State)

VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.

Time frame:
Within 24 hours after completion of the study drug administration
Reported as:
Mean · Scores on a scale
Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Stability of Respiratory State)
Scores on a scalePlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Stability of Respiratory State)2.35 ± 2.772.62 ± 2.791.8 ± 2.022.85 ± 2.93.12 ± 2.13
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Mantel Haenszel · p = 0.11Stratified by the anesthesia type
SecondaryVisual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Subject's Cooperation)

VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.

Time frame:
Within 24 hours after completion of the study drug administration
Reported as:
Mean · Scores on a scale
Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Subject's Cooperation)
Scores on a scalePlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Subject's Cooperation)1.48 ± 1.671.8 ± 2.351.05 ± 1.461.15 ± 1.191.17 ± 1.46
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Mantel Haenszel · p = 0.567Stratified by the anesthesia type
SecondaryScore Evaluation of Satisfaction and Anxiety of the Subject ("I Was Satisfied With This Anesthesia Procedure")

Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.

Time frame:
Within 24 hours after completion of the study drug administration (as much as possible)
Reported as:
Mean · Scores on a scale
Score Evaluation of Satisfaction and Anxiety of the Subject ("I Was Satisfied With This Anesthesia Procedure")
Scores on a scalePlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Score Evaluation of Satisfaction and Anxiety of the Subject ("I Was Satisfied With This Anesthesia Procedure")1.7 ± 0.81.7 ± 11.2 ± 0.41.4 ± 0.71.3 ± 0.7
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Mantel Haenszel · p = 0.044Stratified by the anesthesia type
  • Placebo vs Dexmedetomidine 0.5 mcg/kg · Mantel Haenszel · p = 0.234Stratified by the anesthesia type
SecondaryScore Evaluation of Satisfaction and Anxiety of the Subject ("I Did Not Feel Pain During the Surgery")

Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.

Time frame:
Within 24 hours after completion of the study drug administration (as much as possible)
Reported as:
Mean · Scores on a scale
Score Evaluation of Satisfaction and Anxiety of the Subject ("I Did Not Feel Pain During the Surgery")
Scores on a scalePlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Score Evaluation of Satisfaction and Anxiety of the Subject ("I Did Not Feel Pain During the Surgery")1.2 ± 0.71.2 ± 0.71.2 ± 0.71.4 ± 0.91.2 ± 0.6
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Mantel Haenszel · p = 0.729Stratified by the anesthesia type
SecondaryScore Evaluation of Satisfaction and Anxiety of the Subject ("If You May Undergo a Similar Surgery, the Same Anesthesia Procedure Will be Requested for the Next Time")

Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.

Time frame:
Within 24 hours after completion of the study drug administration (as much as possible)
Reported as:
Mean · Scores on a scale
Score Evaluation of Satisfaction and Anxiety of the Subject ("If You May Undergo a Similar Surgery, the Same Anesthesia Procedure Will be Requested for the Next Time")
Scores on a scalePlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Score Evaluation of Satisfaction and Anxiety of the Subject ("If You May Undergo a Similar Surgery, the Same Anesthesia Procedure Will be Requested for the Next Time")1.7 ± 1.11.5 ± 0.81.3 ± 0.61.5 ± 0.81.2 ± 0.4
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Mantel Haenszel · p = 0.082Stratified by the anesthesia type
SecondaryScore Evaluation of Satisfaction and Anxiety of the Subject ("Assess the Anxiety Level Before Surgery")

Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.

Time frame:
Within 24 hours after completion of the study drug administration (as much as possible)
Reported as:
Mean · Scores on a scale
Score Evaluation of Satisfaction and Anxiety of the Subject ("Assess the Anxiety Level Before Surgery")
Scores on a scalePlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Score Evaluation of Satisfaction and Anxiety of the Subject ("Assess the Anxiety Level Before Surgery")2.2 ± 1.32.2 ± 1.32.2 ± 1.21.8 ± 12 ± 1.2
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Mantel Haenszel · p = 0.451Stratified by the anesthesia type
SecondaryScore Evaluation of Satisfaction and Anxiety of the Subject ("Assess the Anxiety Level During Surgery")

Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.

Time frame:
Within 24 hours after completion of the study drug administration (as much as possible)
Reported as:
Mean · Scores on a scale
Score Evaluation of Satisfaction and Anxiety of the Subject ("Assess the Anxiety Level During Surgery")
Scores on a scalePlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Score Evaluation of Satisfaction and Anxiety of the Subject ("Assess the Anxiety Level During Surgery")1.6 ± 1.11.6 ± 0.81.6 ± 0.91.4 ± 0.91.7 ± 1.1
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Mantel Haenszel · p = 0.873Stratified by the anesthesia type
SecondaryScore Evaluation of Satisfaction and Anxiety of the Subject ("Assess the Anxiety Level After Surgery")

Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.

Time frame:
Within 24 hours after completion of the study drug administration (as much as possible)
Reported as:
Mean · Scores on a scale
Score Evaluation of Satisfaction and Anxiety of the Subject ("Assess the Anxiety Level After Surgery")
Scores on a scalePlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Score Evaluation of Satisfaction and Anxiety of the Subject ("Assess the Anxiety Level After Surgery")1.6 ± 0.91.6 ± 11.6 ± 0.61.3 ± 0.71.5 ± 1
Statistical analysis
  • Placebo vs Dexmedetomidine 1.0 mcg/kg · Mantel Haenszel · p = 0.374Stratified by the anesthesia type

Adverse events

Collected over Adverse events that occurred from the start of treatment to 24 hours after the end of treatment, a median of 67 - 87 mins treatment depending on treatment arms.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/22 (0%)0/22 (0%)19/22 (86.4%)
Dexmedetomidine 0.067 mcg/kg0/23 (0%)1/23 (4.3%)21/23 (91.3%)
Dexmedetomidine 0.25 mcg/kg0/24 (0%)0/24 (0%)24/24 (100%)
Dexmedetomidine 0.5 mcg/kg0/25 (0%)0/25 (0%)22/25 (88%)
Dexmedetomidine 1.0 mcg/kg0/25 (0%)0/25 (0%)25/25 (100%)
Most frequent serious events
Most frequent serious events
EventPlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
SepsisInfections and infestations0/221/230/240/250/25
Most frequent other events
Showing 10 of 37
Most frequent other events
EventPlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kg
Respiratory depressionRespiratory, thoracic and mediastinal disorders12/2211/2312/2410/2511/25
HypotensionVascular disorders5/2212/2311/248/2510/25
BradycardiaCardiac disorders8/2211/239/2410/2511/25
HypertensionVascular disorders5/222/232/243/258/25
HypoxiaRespiratory, thoracic and mediastinal disorders4/223/232/243/253/25
GlossoptosisGastrointestinal disorders3/220/230/242/252/25
TachycardiaCardiac disorders2/223/230/240/250/25
HeadachesNervous system disorders2/221/230/241/250/25
NauseaGastrointestinal disorders2/220/231/240/251/25
Puncture site painGeneral disorders2/220/231/240/250/25

Baseline characteristics

Full Analysis Set\<FAS\>: FAS is defined as all patients who were administered with the study drugs.

Age, Continuous
Age, Continuous(years)PlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kgTotal
Mean69.0 (51 to 86)60.7 (33 to 85)63.8 (27 to 86)60.0 (28 to 80)59.3 (26 to 82)62.4 (26 to 86)
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kgTotal
Female37871338
Male191616181281
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboDexmedetomidine 0.067 mcg/kgDexmedetomidine 0.25 mcg/kgDexmedetomidine 0.5 mcg/kgDexmedetomidine 1.0 mcg/kgTotal
American Indian or Alaska Native000000
Asian2223242525119
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White000000
More than one race000000
Unknown or Not Reported000000
08

Study locations

12 sites
  • Nagoya University Hospital
    Nagoya, Aichi, Japan
  • Asahikawa Medical University Hospital
    Asahikawa, Hokkaido, Japan
  • Sapporo Medical University Hospital
    Sapporo, Hokkaido, Japan
  • Kochi Medical School Hospital
    Nangoku, Kochi, Japan
  • Shinshul University Hospital
    Matsumoto, Nagano, Japan
  • Shimane University Hospital
    Izumo, Shimane, Japan
  • Tottori University Hospital
    Yonago, Tottori, Japan
  • Japanese Red Cross Kyoto Daini Hospital
    Kyoto, Japan
  • University of Miyazaki Hospital
    Miyazaki, Japan
  • Okayama University Hospital
    Okayama, Japan
  • Kitano Hospital, The Tazuke Kofukai Medical Research Institute
    Osaka, Japan
  • Nippon Medical University Hospital
    Tokyo, Japan
09

References and documents

Publications

  • Inagaki Y, Yamakage M, Sakamoto A, Okayama A, Oya N, Hiraoka T, Morita K. The Efficacy and Safety of Dexmedetomidine for Sedation During Surgery Under Epidural or Spinal Anesthesia: A Randomized, Double-Blind, Placebo-Controlled Study. Yonago Acta Med. 2022 Jan 4;65(1):14-25. doi: 10.33160/yam.2022.02.002. eCollection 2022 Feb. PubMed 35221757 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2011 to primary completion in Nov 2011, 5 months.

Results were first posted in Mar 2021, 9 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2011
First posted
Sep 22, 2011
StartActual
Jun 3, 2011
Primary completionActual
Nov 18, 2011
CompletionActual
Nov 18, 2011
Results first posted
Mar 22, 2021
Last update
Mar 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01438957
Lead sponsor
Pfizer
Collaborators
Maruishi Pharmaceutical
Responsible party
Sponsor
First posted
Sep 22, 2011
Start date
Jun 3, 2011
Primary completion
Nov 18, 2011
Completion
Nov 18, 2011
Results posted
Mar 22, 2021
Last update
Mar 22, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion